UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

The New England journal of medicine, 2014-07, Vol.371 (3), p.224-233

2014

Volltextzugriff (PDF)

Symptomatic Treatment With Lanreotide Microparticles in Inoperable Bowel Obstruction Resulting From Peritoneal Carcinomatosis: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Journal of clinical oncology, 2012-12, Vol.30 (35), p.4337-4343

2012

Volltextzugriff (PDF)

Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy of Lanreotide 30 mg PR in the Treatment of Pancreatic and Enterocutaneous Fistulae

Annals of surgery, 2009-12, Vol.250 (6), p.872-877

2009

Volltextzugriff (PDF)

Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy

Clinical therapeutics, 2006-10, Vol.28 (10), p.1485-1508

2006

Volltextzugriff (PDF)

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly

Clinical endocrinology (Oxford), 2008-08, Vol.69 (2), p.299-305

2008

Volltextzugriff (PDF)

Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty

European journal of endocrinology, 2006-01, Vol.154 (1), p.119-124

2006

Volltextzugriff (PDF)

Fertility of Women Treated during Childhood with Triptorelin (Depot Formulation) for Central Precocious Puberty: The PREFER Study

Hormone research in paediatrics, 2021-04, Vol.93 (9-10), p.529-538

2021

Volltextzugriff (PDF)

Long-acting lanreotide in adolescent girls with constitutional tall stature

Hormone research, 2009-01, Vol.71 (4), p.228-236

2009

Volltextzugriff (PDF)

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

The American journal of gastroenterology, 2000-11, Vol.95 (11), p.3276-3281

2000

Volltextzugriff (PDF)

The CLARINET study: Assessing the effect of lanreotide autogel on tumor progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.TPS4153-TPS4153

2012

Volltextzugriff (PDF)

Use of Lanreotide for the Treatment of Gastrointestinal Fistulae

Annals of surgery, 2011-01, Vol.253 (1), p.211-212

2011

Volltextzugriff (PDF)

A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate

Hormone research in paediatrics, 2016-01, Vol.86 (3), p.188-195

2016

Volltextzugriff (PDF)

Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.4107-4107

2014

Volltextzugriff (PDF)

Final Height after Long-Term Treatment with Triptorelin Slow Release for Central Precocious Puberty: Importance of Statural Growth after Interruption of Treatment

The journal of clinical endocrinology and metabolism, 1999-06, Vol.84 (6), p.1973-1978

1999

Volltextzugriff (PDF)

Efficacy and Tolerability of the Long-Acting Somatostatin Analog Lanreotide in Acromegaly. A 12-Month Multicenter Study of 58 Acromegalic Patients

Pituitary, 2000-05, Vol.2 (4), p.269

2000

Volltextzugriff (PDF)

Treatment of carcinoid syndrome : A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance

Cancer, 2000-02, Vol.88 (4), p.770-776

2000

Volltextzugriff (PDF)

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

The American journal of gastroenterology, 2000, Vol.95 (11), p.3276-3281

2000

Volltextzugriff (PDF)

Symptomatic Treatment With Lanreotide Microparticles in Inoperable Bowel Obstruction Resulting From Peritoneal Carcinomatosis: A Randomized, Double-blind, Placebo-controlled Phase III Study

Obstetrical & gynecological survey, 2013-06, Vol.68 (6), p.437-438

2013

Volltextzugriff (PDF)

Antiproliferative effects of lanreotide Autogel in patients with enteropancreatic neuroendocrine tumours: results of CLARINET, a large international phase 3 study

Endocrine Abstracts, 2014-04

2014

Volltextzugriff (PDF)

Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis

Fertility and sterility, 2004-02, Vol.81 (2), p.297-304

2004

Volltextzugriff (PDF)

Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer

Hormone research, 2004-01, Vol.62 (5), p.252-258

2004

Volltextzugriff (PDF)

Efficacy of lanreotide 30 mg on prevention of pain relapse after oral refeeding in patients with necrotizing acute pancreatitis. A phase II prospective multicentre study

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2004-01, Vol.4 (3-4), p.229-232

2004

Volltextzugriff (PDF)

Efficacy of Lanreotide 30 mg on Prevention of Pain Relapse after Oral Refeeding in Patients with Necrotizing Acute Pancreatitis

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2004, Vol.4 (3-4), p.229-232

2004

Volltextzugriff (PDF)

Treatment of carcinoid syndrome

Cancer, 2000-02, Vol.88 (4), p.770-776

2000

Volltextzugriff (PDF)

Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect

Acta endocrinologica (Copenhagen), 1993-04, Vol.128 (4), p.351-354

1993

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Symptomatic Treatment With Lanreotide Microparticles in Inoperable Bowel Obstruction Resulting From Peritoneal Carcinomatosis: A Randomized, Double-Blind, Placebo-Controlled Phase III Study

Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy of Lanreotide 30 mg PR in the Treatment of Pancreatic and Enterocutaneous Fistulae

Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly

Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty

Fertility of Women Treated during Childhood with Triptorelin (Depot Formulation) for Central Precocious Puberty: The PREFER Study

Long-acting lanreotide in adolescent girls with constitutional tall stature

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

The CLARINET study: Assessing the effect of lanreotide autogel on tumor progression-free survival in patients with nonfunctioning gastroenteropancreatic neuroendocrine tumors

Use of Lanreotide for the Treatment of Gastrointestinal Fistulae

A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate

Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study

Final Height after Long-Term Treatment with Triptorelin Slow Release for Central Precocious Puberty: Importance of Statural Growth after Interruption of Treatment

Efficacy and Tolerability of the Long-Acting Somatostatin Analog Lanreotide in Acromegaly. A 12-Month Multicenter Study of 58 Acromegalic Patients

Treatment of carcinoid syndrome : A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance

The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

Symptomatic Treatment With Lanreotide Microparticles in Inoperable Bowel Obstruction Resulting From Peritoneal Carcinomatosis: A Randomized, Double-blind, Placebo-controlled Phase III Study

Antiproliferative effects of lanreotide Autogel in patients with enteropancreatic neuroendocrine tumours: results of CLARINET, a large international phase 3 study

Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis

Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer

Efficacy of lanreotide 30 mg on prevention of pain relapse after oral refeeding in patients with necrotizing acute pancreatitis. A phase II prospective multicentre study

Efficacy of Lanreotide 30 mg on Prevention of Pain Relapse after Oral Refeeding in Patients with Necrotizing Acute Pancreatitis

Treatment of carcinoid syndrome

Non-responsiveness of serum gonadotropins and testosterone to pulsatile GnRH in hemochromatosis suggesting a pituitary defect

Suchergebnisse filtern